Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tectonic family member 2 (TCTN2) is a type I transmembrane protein localized at the ciliary transition zone, where it forms part of a multiprotein barrier complex essential for ciliogenesis and signal transduction, specifically regulating Hedgehog and Wnt pathways[1][2]. TCTN2 is necessary for ciliary function and organ development; disruptions cause ciliopathies including Meckel syndrome type 8 and Joubert syndrome 24, characterized by developmental, neurological, and renal abnormalities[2][3]. In cancer, TCTN2 is upregulated and acts as an oncogene, promoting anchorage-independent growth, invasiveness, suppressing apoptosis, and enhancing cilia formation in various tumor types[1]. Downregulation of TCTN2 impairs cilia assembly, reduces proliferation, and sensitizes to apoptosis in cancer cells, supporting its exploration as a cancer therapeutic target and potential biomarker[1]. No direct drug modulators are currently reported; epigenetic editing of TCTN2 expression has shown therapeutic potential in preclinical studies[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tectonic family member 2 (TCTN2).